GLP-1 Telehealth Funding & M&A Database (2026)

Last verified: May 6, 2026 · Next scheduled update: June 1, 2026 · Curated by: Weight Loss Provider Guide research team

Source standard: SEC filings, company investor releases, primary press releases, and reputable business reporting. Conflicts flagged. Estimates labeled.

If you're on deadline and you need a real number for a GLP-1 telehealth deal, this is the page to bookmark. The GLP-1 Telehealth Funding & M&A Database consolidates the funding rounds, acquisitions, public-company revenue figures, and restructurings we could verify in the GLP-1 telehealth segment, with primary sources beside each entry and a date stamped on every row. Conflicts flagged. Estimates labeled. No paywalls.

Quick stats

What is the GLP-1 Telehealth Funding & M&A Database?

The GLP-1 Telehealth Funding & M&A Database is a curated, source-graded ledger of funding rounds, acquisitions, public-company revenue disclosures, valuations, restructurings, and litigation involving companies that prescribe GLP-1 medications via telehealth. It is built for journalists, analysts, and corp dev teams who need to cite a number with the primary source attached.

Free GLP-1 telehealth funding maps already exist on the open web. This database exists because the open web is still fragmented — funding maps, SEC filings, investor releases, lawsuits, revenue disclosures, and private-database snippets aren't combined into one row-level, source-graded, last-verified-dated tracker with conflict notes. That's our wedge.

At a glance: the master funding & deal table

The working view of every notable GLP-1 telehealth company tracked, with their reported totals, latest material event, primary source, and confidence grade. Each company has an anchor link so you can deep-link straight to the row you're citing.

GLP-1 telehealth M&A 2026 (and 2023–2025)

Four material acquisitions have shaped the GLP-1 telehealth segment since 2023: WeightWatchers' purchase of Sequence (March 2023, $132M transaction value), Hims & Hers' acquisition of ZAVA (announced June 2025, closed mid-2025, $258.0M accounting purchase price per Hims' Q3 2025 10-Q), Remedy Meds' all-stock agreement to acquire Thirty Madison (announced September 3, 2025, $500M+ — close status not independently verified here), and Hims & Hers' pending acquisition of Eucalyptus (announced February 19, 2026, up to $1.15B, closing expected mid-2026).

Hims & Hers / Eucalyptus — up to $1.15B (announced Feb 19, 2026; pending)

The largest announced transaction in the segment so far. Hims & Hers (NYSE: HIMS) signed a definitive agreement to acquire Eucalyptus, the Australian-based parent of GLP-1 weight-loss brand Juniper (women's), Pilot (men's), Kin (fertility), and others. The deal is structured as:

• ·~$240 million in cash at closing
• ·~$710 million in guaranteed deferred payments over 18 months post-close
• ·Up to $200 million in earnout payments tied to financial targets through early 2029
• ·Total enterprise value: up to $1.15 billion

Eucalyptus disclosed an annualized revenue run-rate north of $450 million USD with triple-digit year-over-year ARR growth in each quarter of 2025. Hims plans to fund most of the cash portion from existing cash and US operating cash flows. Closing is expected mid-calendar-year 2026, subject to regulatory approvals. Treat this row as announced/pending until close is independently verified.

Safe citation:"Hims & Hers announced an agreement to acquire Eucalyptus in a transaction valued at up to $1.15 billion, including approximately $240 million in cash at closing, with the remainder structured as deferred payments and performance-based earnouts through early 2029, according to the company's investor release. Closing is expected mid-2026, subject to regulatory approvals."

Sources: Hims & Hers investor release (Feb 19, 2026); Hims SEC Form 8-K (Feb 19, 2026); CNBC; MobiHealthNews; STAT; MedCity News.

Hims & Hers / ZAVA — $258.0M accounting purchase price (closed mid-2025)

The first leg of the European push. Hims acquired ZAVA, a London-based digital health platform serving the UK, Germany, France, and Ireland. The deal closed in mid-2025 and added roughly 1.3 million active customers to the Hims base — about 50% of its US footprint at the time.

The financial terms were not initially disclosed at announcement. However, Hims & Hers' Q3 2025 Form 10-Q reports the ZAVA purchase price for accounting purposes was €219.2 million ($258.0 million), including:

• ·€142.2 million ($167.3 million) cash paid upfront
• ·€77.0 million ($90.7 million) contingent consideration
• ·Plus a potential earn-out payable in cash of up to €117.7 million, tied to revenue and adjusted EBITDA targets measured for fiscal years 2025, 2026, and 2027

Safe citation:"Hims & Hers acquired ZAVA in July 2025. The company's Q3 2025 Form 10-Q reports a purchase price for accounting purposes of €219.2 million, or $258.0 million, including €142.2 million / $167.3 million cash paid upfront and €77.0 million / $90.7 million in contingent consideration, plus potential earn-out payable in cash of up to €117.7 million."

Sources: Hims & Hers SEC Form 10-Q for the quarter ended Sep 30, 2025 (note on business combinations); Hims investor release (Jun 3, 2025); CNBC; FierceHealthcare.

Remedy Meds / Thirty Madison — $500M+ all-stock (announced Sep 3, 2025; close status to verify)

A roll-up under the radar. Remedy Meds — a New Jersey-based GLP-1 telehealth company founded in May 2024 by Haris Memon — agreed to acquire Thirty Madison, the parent of Nurx (women's health), Keeps (men's hair loss), Cove (migraine), Evens (GI), and Picnic (allergies). The all-stock deal was announced at a transaction value just north of $500 million, with closing expected in Q4 2025.

The combined company is projecting roughly $670 million in annual revenue at announcement (Remedy Meds at $450M+ for 2025; Thirty Madison at $220M+). This deal matters because Thirty Madison was once a venture-backed unicorn ($1B valuation in 2021 after a $140M Series C), and it was being absorbed by a one-year-old GLP-1-led company. Close status: [NEEDS VERIFICATION] — we have the announcement source but not an independent close confirmation.

Safe citation:"Remedy Meds announced a definitive all-stock agreement to acquire Thirty Madison, valued at just north of $500 million, on September 3, 2025; closing was expected in Q4 2025. Cite close status only with a separate confirming source."

Sources: PRNewswire (Sep 3, 2025); Axios; FierceHealthcare; MobiHealthNews; Cooley LLP and Weil, Gotshal & Manges advisory disclosures.

WeightWatchers / Sequence — $132M (announced Mar 2023; closed Apr 2023)

The deal that started consolidation. WeightWatchers acquired Sequence, a telehealth platform for clinical weight management, in a transaction valued at $132 million per the company's announcement, including a minimum cash component. Some downstream sources cite an effective net purchase price of $106M after adjustments. We carry both figures and link to WW's primary release.

Sequence has since been rebranded WeightWatchers Clinic and is the GLP-1 backbone of the parent company's clinical revenue post-bankruptcy.

Safe citation:"WeightWatchers announced the acquisition of Sequence in March 2023 in a transaction valued at $132 million, according to the company's release; the asset has since been rebranded WeightWatchers Clinic."

Sources: WW International corporate release (Mar 2023); subsequent SEC filings; FierceHealthcare.

Public company GLP-1 revenue: Hims, LifeMD, WeightWatchers, Mangoceuticals

Public-company revenue is the safest data on this page because it comes from SEC filings. Hims & Hers reported approximately $2.35 billion in total FY2025 revenue, with weight loss called out as a major contributor. LifeMD reported $194.1 million in FY2025 telehealth revenue. WW International emerged from a prepackaged Chapter 11 in mid-2025 and is rebuilding its clinical business under the WeightWatchers Clinic brand. Mangoceuticals launched its branded GLP-1 access pathway in November 2025 and is early-stage.

Hims weight loss revenue 2026: what is actually disclosed?

For searchers looking for Hims Hers GLP-1 revenue or Hims weight loss revenue 2026, here is the clean answer: Hims & Hers disclosed total FY2025 revenue and weight-loss segment context in its earnings release, but did not publish a clean FY2025 GLP-1-only revenue split. FY2026 guidance is for total revenue of $2.7B–$2.9B, not a GLP-1-specific number.

Hims & Hers GLP-1 revenue and weight-loss revenue

Stated vs verified — Hims & Hers

LifeMD (NASDAQ: LFMD) — telehealth revenue and GLP-1 driver

WW International / WeightWatchers (NASDAQ: WW) — Chapter 11 and rebuild

WW International filed a prepackaged Chapter 11 on May 6, 2025, to eliminate approximately $1.15 billion of pre-petition debt (out of roughly $1.6 billion). The reorganization plan was confirmed on June 17, 2025 — about 42 days after filing. The company subsequently rebranded its Sequence asset as WeightWatchers Clinic.

Ro Series E funding: what was actually disclosed?

Public database profiles report approximately $1.03 billion in Ro funding across seven rounds. Ro's own press releases confirm a $500 million Series D in March 2021 (bringing total fundraising to ~$876M) and a $150 million additional financing in February 2022 at a reported ~$7 billion valuation. Some search results label the 2022 round a "Series E"; Ro's own release calls it an additional financing from existing investors. The cleanest characterization: $500M Series D in March 2021 at a $5B valuation, followed by a $150M financing in February 2022 at a reported $7B valuation.

Safe citation:"Public database profiles report Ro funding totaling approximately $1.03 billion across seven rounds. Ro's own press releases confirm a $500 million Series D in March 2021 at a reported $5 billion valuation and a $150 million additional financing in February 2022, with the 2022 valuation reported in news coverage at approximately $7 billion. Ro has not disclosed a new priced primary round since."

Material 2024–2025 events: Eli Lilly partnered with Ro in December 2024 to distribute Zepbound vials via LillyDirect. Novo Nordisk maintained its NovoCare Wegovy partnership with Ro in mid-2025 — notable because Novo simultaneously ended its Hims & Hers partnership over compounding concerns. Per Sacra's 2024 estimate (independent analyst, not a Ro disclosure), Ro generated approximately $598 million in revenue in 2024 (+66% YoY), with roughly $370 million attributable to GLP-1. Cite as Sacra's estimate.

Mochi Health funding — a public conflict, not a clean number

Public funding databases give three different totals for Mochi Health: $500K (Wellfound), $650K (Tracxn / Crunchbase Seed entry, March 2022), and $1.15M (PitchBook public snippet). The company has not, to our knowledge, issued a primary-source release confirming a clean cumulative total. Until that is verified, we publish the conflict instead of pretending certainty.

What we can confirm

• ·Founded: 2022; founder/CEO listed as Myra Ahmad in public company-profile sources
• ·Headquarters: San Francisco, CA
• ·Employees: ~80 (per PitchBook)
• ·Provider network: 500+ affiliated providers (per company release, Nov 12, 2025)
• ·Reported Seed round: ~March 2022, between $500K and $650K depending on source
• ·Most recent product event: Platform expansion to 15 new specialty areas on November 12, 2025
• ·Litigation: Named defendant in Eli Lilly's April 23, 2025 suit; on April 13, 2026, court partially denied Mochi's renewed motion to dismiss, allowing Lanham Act and California UCL claims to proceed.

Safe citation:"Public funding databases report a March 2022 Seed or Pre-Seed round, but the cumulative total conflicts across sources — ranging from $500,000 to $1.15 million — and Weight Loss Provider Guide has not verified a primary-source funding total as of May 6, 2026."

eMed — the $200M Series A that just repriced the segment

On March 26, 2026, employer-focused GLP-1 telehealth platform eMed closed a $200 million Series A at a $2 billion+ post-money valuation, led by AON Consulting. The round vaulted eMed into unicorn status. CEO is former X CEO Linda Yaccarino; Founding Chief Wellness Officer is Tom Brady.

Safe citation:"eMed closed a $200 million Series A at a $2 billion+ valuation on March 26, 2026, led by AON Consulting, per the company's release. The company-reported member adherence figure above 90% should be cited as company-reported."

Other private funding rounds worth citing

Below are the next-largest private rounds in the segment, each with the lead investor, deal size, and primary source. These are the rows journalists most often need quickly when writing market maps or funding round-ups.

Bankruptcies, restructurings, and litigation tracker

One material bankruptcy and one major litigation cluster have shaped the segment so far. WW International filed a prepackaged Chapter 11 on May 6, 2025, with its plan confirmed June 17, 2025. Eli Lilly sued four compounded GLP-1 telehealth providers in April 2025; in April 2026 the court partially denied Mochi Health's renewed motion to dismiss, allowing Lanham Act and California UCL claims to proceed.

Eli Lilly v. four telehealth defendants

On April 23, 2025, Eli Lilly filed lawsuits in the U.S. District Court for the Northern District of California against four telehealth companies — Mochi Health Corp., Fella Health and Delilah, Willow Health Services, and Henry Meds — alleging unfair competition, false advertising under California law and the federal Lanham Act, and corporate-practice-of-medicine violations related to compounded versions of Lilly's tirzepatide (Mounjaro/Zepbound).

FDA enforcement timeline (compounded GLP-1 segment)

Valuation confidence — what's safe to cite as "current"

Valuation is the field journalists get burned on most often, because old private valuations get cited as if they're current. The table below shows what each valuation reflects, when it was set, and how to phrase it accurately. Treat valuations as time-stamped evidence, not evergreen facts.

How much has GLP-1 telehealth raised in total?

Companies operating GLP-1 telehealth or virtual weight-management programs have raised more than $2 billion in disclosed venture and growth funding through May 2026. The number is concentrated heavily in Ro (~$1.03B database-reported) and Noom (~$540M Series F in 2021), with eMed's March 2026 Series A ($200M) representing the largest single GLP-1-specific round.

Which GLP-1 telehealth numbers are safe to cite?

Funding, revenue, valuation, market cap, and acquisition price are five different things. Treat them that way. Below is the citation friction-reducer journalists actually need: risky vs. safer wording for the most-mis-cited claims in the segment.

Copy-ready citation block

You may cite this database with attribution. For row-level claims, please also link the original primary source listed in the row (SEC filing, investor release, or press release).

Methodology and source hierarchy

Every row is graded by source quality. SEC filings and official investor releases rank highest. Reputable news and company press releases follow. Private database snippets are used only for discovery, with conflict notes and verification flags. Where sources disagree, we publish the disagreement instead of forcing a single number.

Inclusion criteria

A company qualifies if it meets all three:

1. Telehealth-delivered care. The company prescribes via virtual visit (synchronous or asynchronous), not in-person primary care.
2. GLP-1 receptor agonist offering. The company offers semaglutide, tirzepatide, liraglutide, orforglipron, or branded GLP-1 medication for weight management or type 2 diabetes.
3. Disclosed financial event. The company has at least one publicly disclosed funding round, M&A event, public-company filing, or material restructuring.

Source hierarchy

Update cadence

• ·Monthly full pass: first business day of each month. Rows are rechecked; rows that materially changed get an updated last-verified date and change-log entry.
• ·Within 72 hours of material event: earnings disclosures, funding announcements, M&A deals, bankruptcies, regulatory actions, lawsuits.
• ·Earnings cycles: heavy update windows in mid-February, early May, early August, and early November as public companies file quarterly results.

How to verify the public-company entries on this page

Every public-company entry can be re-verified from these source documents. We recommend opening the linked filing yourself before citing — that is how editors will fact-check you anyway.

2026 change log and corrections

Corrections log

Frequently asked questions